SCHEMBL10273801

SCHEMBL10273801

CCCc1cccc(N(C)C(=O)Cc2ccccc2)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.44
ITGA4 P13612 1/20 0.44
SIGMAR1 Q99720 2/20 0.44
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.43
NLRP3 Q96P20 1/20 0.43
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
TP53 P04637 1/20 0.43
POLQ O75417 2/20 0.43
TRPM8 Q7Z2W7 1/20 0.41
CNR2 P34972 1/20 0.41
NPC1 O15118 1/20 0.41
JAK2 O60674 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
PAX8 Q06710 1/20 0.41
ALOX5 P09917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15676809 0.88 SIGMAR1 (0.56) ITGB1ITGA4SIGMAR1ALDH1A1LMNA
SCHEMBL1692108 0.84 POLQ (0.45) ITGB1ITGA4SIGMAR1ALDH1A1LMNA
SCHEMBL14039474 0.82 KMT2A (0.52) SIGMAR1ALDH1A1NPC1HTTRAB9A
SCHEMBL8263373 0.82 ALDH1A1 (0.58) ALDH1A1LMNAROCK2ROCK1POLQ
SCHEMBL1696796 0.81 HTR1A (0.45) SIGMAR1ROCK2ROCK1TP53RAB9A
SCHEMBL18970326 0.81 ITGB1 (0.48) ITGB1ITGA4SIGMAR1ALDH1A1LMNA
SCHEMBL1696949 0.79 MEN1 (0.55) SIGMAR1ALDH1A1NPC1RAB9A
SCHEMBL1697001 0.78 SIGMAR1 (0.42) SIGMAR1
SCHEMBL1696343 0.77 L3MBTL1 (0.55) ALDH1A1NPC1HTTRAB9A
SCHEMBL20349603 0.76 ALDH1A1 (0.52) ALDH1A1LMNANLRP3ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 ITGB1 2172/4885ITGA4 1739/4885SIGMAR1 4349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.